September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Entrectinib Granted Priority Review by FDA for NTRK+ Tumors and ROS1+ NSCLC
February 20th 2019Entrectinib has been granted a priority review designation by the FDA as a therapy for select adult and pediatric patients with <em>NTRK</em> fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic <em>ROS1</em>-positive non–small cell lung cancer, according to Genentech, the developer of the multikinase inhibitor.
Read More
The Role of Liquid Biopsy in NSCLC Continues to Emerge
February 12th 2019In a presentation during the 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care symposium, Bob T. Li, MD, MPH, explained ctDNA’s growing importance in lung cancer, given the disease’s challenging prognosis.
Read More
Honing Liquid Biopsies for Application in Cancer Detection, Monitoring
February 9th 2019Liquid biopsies have evolved beyond finding genotypes and have moved into the cancer detection and monitoring spaces, according to Geoffrey R. Oxnard, MD, medical oncologist at the Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School.
Read More
IMpower150 Data for Immunotherapy Quadruplet in EGFR-Mutant Lung Cancer
February 5th 2019Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
Watch
FDA Expands Pemetrexed Indication for Frontline Immunochemotherapy Combo in NSCLC
January 31st 2019Based on data from the phase III KEYNOTE-189 trial, the FDA has expanded the approval for pemetrexed injection in combination with pembrolizumab and platinum-based chemotherapy to include the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without <em>EGFR</em> or <em>ALK</em> alterations.
Read More